271 related articles for article (PubMed ID: 18400849)
1. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.
Keck ZY; Li TK; Xia J; Gal-Tanamy M; Olson O; Li SH; Patel AH; Ball JK; Lemon SM; Foung SK
J Virol; 2008 Jun; 82(12):6061-6. PubMed ID: 18400849
[TBL] [Abstract][Full Text] [Related]
2. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
3. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK
PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875
[TBL] [Abstract][Full Text] [Related]
4. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
5. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.
Keck ZY; Pierce BG; Lau P; Lu J; Wang Y; Underwood A; Bull RA; Prentoe J; Velázquez-Moctezuma R; Walker MR; Luciani F; Guest JD; Fauvelle C; Baumert TF; Bukh J; Lloyd AR; Foung SKH
PLoS Pathog; 2019 May; 15(5):e1007772. PubMed ID: 31100098
[TBL] [Abstract][Full Text] [Related]
6. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.
Owsianka AM; Tarr AW; Keck ZY; Li TK; Witteveldt J; Adair R; Foung SKH; Ball JK; Patel AH
J Gen Virol; 2008 Mar; 89(Pt 3):653-659. PubMed ID: 18272755
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.
Pierce BG; Keck ZY; Wang R; Lau P; Garagusi K; Elkholy K; Toth EA; Urbanowicz RA; Guest JD; Agnihotri P; Kerzic MC; Marin A; Andrianov AK; Ball JK; Mariuzza RA; Fuerst TR; Foung SKH
J Virol; 2020 Oct; 94(22):. PubMed ID: 32878891
[TBL] [Abstract][Full Text] [Related]
8. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.
Hadlock KG; Lanford RE; Perkins S; Rowe J; Yang Q; Levy S; Pileri P; Abrignani S; Foung SK
J Virol; 2000 Nov; 74(22):10407-16. PubMed ID: 11044085
[TBL] [Abstract][Full Text] [Related]
9. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
J Virol; 2018 May; 92(9):. PubMed ID: 29467319
[TBL] [Abstract][Full Text] [Related]
10. A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.
Keck ZY; Olson O; Gal-Tanamy M; Xia J; Patel AH; Dreux M; Cosset FL; Lemon SM; Foung SK
J Virol; 2008 Jun; 82(12):6067-72. PubMed ID: 18385242
[TBL] [Abstract][Full Text] [Related]
11. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.
Johansson DX; Voisset C; Tarr AW; Aung M; Ball JK; Dubuisson J; Persson MA
Proc Natl Acad Sci U S A; 2007 Oct; 104(41):16269-74. PubMed ID: 17911260
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.
Tarr AW; Owsianka AM; Timms JM; McClure CP; Brown RJ; Hickling TP; Pietschmann T; Bartenschlager R; Patel AH; Ball JK
Hepatology; 2006 Mar; 43(3):592-601. PubMed ID: 16496330
[TBL] [Abstract][Full Text] [Related]
13. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.
Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK
J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044
[TBL] [Abstract][Full Text] [Related]
14. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
Bose M; Mullick R; Das S; Das S; Karande AA
Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
[TBL] [Abstract][Full Text] [Related]
15. Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2.
Keck ZY; Li TK; Xia J; Bartosch B; Cosset FL; Dubuisson J; Foung SK
J Virol; 2005 Nov; 79(21):13199-208. PubMed ID: 16227243
[TBL] [Abstract][Full Text] [Related]
16. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.
Helle F; Goffard A; Morel V; Duverlie G; McKeating J; Keck ZY; Foung S; Penin F; Dubuisson J; Voisset C
J Virol; 2007 Aug; 81(15):8101-11. PubMed ID: 17522218
[TBL] [Abstract][Full Text] [Related]
17. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
18. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
[TBL] [Abstract][Full Text] [Related]
19. Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein.
Iacob RE; Keck Z; Olson O; Foung SK; Tomer KB
Biochim Biophys Acta; 2008 Mar; 1784(3):530-42. PubMed ID: 18230369
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions.
Keck ZY; Op De Beeck A; Hadlock KG; Xia J; Li TK; Dubuisson J; Foung SK
J Virol; 2004 Sep; 78(17):9224-32. PubMed ID: 15308717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
